Randomized Trialhigh evidence
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.
The American journal of psychiatry·July 29, 2026·PMID 42522065
Why it mattersGLP-1 receptor agonists are widely used for metabolic conditions, and emerging evidence suggests they may reduce alcohol intake. This trial provides early controlled data on semaglutide's effects in a treatment-seeking AUD population, supporting further investigation into repurposing these agents for addiction.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled